Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.
Cramer also likes Total but he's not crazy about Antares Pharma, Chesapeake Energy or EMC.
Investors need to ignore the bad news because the time to invest is now, Cramer said.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the submission of a New Drug Application (NDA) to the U.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.
Cramer also says to avoid Antares Pharma and Frontier Communications but would go with Apple and Linn Energy.
The optimists think going over the 'fiscal cliff' is no big deal. Cramer thinks they're dead wrong.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from an open-label, randomized, crossover study comparing the systemic availability of MTX Medi-Jet to oral methotrexate (MTX) in adult patients with...
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.
Antares Pharma, Inc. (NASDAQ: ATRS) today reported financial and operating results for the third quarter ended September 30, 2012.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2012 financial results before the market opens on Wednesday, November 7, 2012, and host a conference call shortly thereafter at 8:30...
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the closing of its previously announced firm commitment underwritten public offering of 12,500,000 shares of the Company’s common stock at a purchase price of ...
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has priced a firm commitment underwritten public offering of 12,500,000 shares of the Company’s common stock at a purchase price to the public of $4.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced a public offering of shares of its common stock.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that its partner Pfizer Inc.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from an Actual Human Use (AHU) study for VIBEX Methotrexate (MTX).
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.
Antares Pharma (Nasdaq:ATRS) has been downgraded by TheStreet Ratings from from a hold to sell.
Antares Pharma, Inc. (NASDAQ: ATRS) today reported financial and operating results for the second quarter ended June 30, 2012.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2012 financial results before the market opens on Wednesday, August 8, 2012, and host a conference call shortly thereafter at 8:30...
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Jonathan S.
Antares Pharma (Nasdaq:ATRS) hit a new 52-week high Tuesday as it is currently trading at $3.84, above its previous 52-week high of $3.75 with 325,626 shares traded as of 9:40 a.m. ET. Average volume has been one million shares over the past 30 days.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a human factors usability study for VIBEX Methotrexate (MTX), a proprietary auto injector product designed to self-administer a rapid ...
The market is pricing in a weak 2007, but near-term downside is limited and shares should lift.
The major averages end below their session highs.
Investors question whether it's time for another large buy.
Altiris takes off, while Radware slumps.
The deal offers a 22% premium.
